Headlines:
Tag: Treatment
ImmuneMed's 'hzVSF,' Used for Treatment of COVID-19 Pneumonia Patients

ImmuneMed's 'hzVSF,' Used for Treatment of COVID-19 Pneumonia Patients

March 30, 2020 Economie

- 'Approved' for treatment purpose usage at Yonsei University Hospital after Seoul National University Hospital, Yeungnam University Hospital and Chungnam National University ...

Lees verder
CHMP Adopts Positive Opinion for Treatment of Acute Angioedema Attacks in Children With Hereditary Angioedema With RUCONEST®

CHMP Adopts Positive Opinion for Treatment of Acute Angioedema Attacks in Children With Hereditary Angioedema With RUCONEST®

March 27, 2020 Economie

LEIDEN, Netherlands, March 27, 2020 /PRNewswire/ -- Pharming announces the Committee for Medicinal Products for Human Use (CHMP), an advisory committee of the European Medicine ...

Lees verder
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcino

European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcino

October 28, 2019 Economie

Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with ...

Lees verder
EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

EVENITY® (romosozumab) Receives Positive CHMP Opinion for the Treatment of Severe Osteoporosis in Postmenopausal Women at High Risk of Fracture

October 19, 2019 Economie

BRUSSELS and THOUSAND OAKS, California, Oct. 18, 2019 /PRNewswire/ -- UCB and Amgen today announced that following a re-examination procedure, the Committee for Medicinal ...

Lees verder
International Atherosclerosis Society & Residual Risk Reduction Initiative Publish Consensus Statement on New Treatment for Residual Cardiovascul

International Atherosclerosis Society & Residual Risk Reduction Initiative Publish Consensus Statement on New Treatment for Residual Cardiovascul

September 2, 2019 Economie

MILAN and BASEL, Switzerland, Sept. 2, 2019 /PRNewswire/ -- A new highly selective treatment, a peroxisome proliferator-activated receptor alpha modulator (SPPARM-alpha) ...

Lees verder
TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer's Disease a

TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer's Disease a

April 21, 2019 Economie

NEW YORK and LONDON, April 18, 2019 /PRNewswire/ -- TAU BIO-LOGIC CORP. announced today that in collaboration with the UK-based group LifeArc, it has successfully humanized a ...

Lees verder
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

February 11, 2019 Economie

Market Development Veteran Lisa Rogan Joins Nuvaira's Executive Team MINNEAPOLIS, Feb 11, 2019 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic medical devices to ...

Lees verder
Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome

September 21, 2018 Economie

TOKYO, September 21, 2018 /PRNewswire/ -- If approved, mogamulizumab would be the first biologic agent targeting CCR4 to be available for patients in Europe.   Kyowa Hakko ...

Lees verder
Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure

Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure

September 16, 2018 Economie

LISLE, Illinois, Sept. 14, 2018 /PRNewswire/ -- Endotronix, Inc. , a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the ...

Lees verder
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

August 8, 2018 Economie

TOKYO, August 8, 2018 /PRNewswire/ -- - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in ...

Lees verder
Nieuwe berichten
BizPress.nl